A light at the end of the tunnel

The article by van Laethem et al in this issue (see page 747) describes a well conducted study using the argon plasma coagulator (APC) to treat Barrett’s oesophagus in 31 patients. However, complete eradication of Barrett’s mucosa was only confirmed histologically in 19 (61%), the remainder having a few residual Barrett’s glands under the new squamous epithelium. Seventeen of those with apparent complete endoscopic and histological eradication at early follow up were biopsied again a year later, eight (47%) of whom had relapsing islands of Barrett’s metaplasia of whom had relapsing islands of Barrett’s metaplasia. These results lead to the same conclusion as that emerging from many recent studies on the endoscopic treatment of Barrett’s oesophagus using a variety of techniques. It is possible to destroy specialised columnar epithelium in the oesophagus with a range of techniques and the treated areas heal with regeneration of squamous epithelium. However, there is a high risk of leaving some Barrett’s glands under the regenerated squamous epithelium. This raises two crucial questions. Firstly, does it matter if a few glands are left behind and, secondly, can any of the treatment options be modified to give reliable destruction of all the Barrett's glands without any unacceptable complications.

The first question is tackled in the paper, although it is very difficult to answer. Statistically, if the number of Barrett’s glands is drastically reduced, one would expect the risk of neoplastic transformation also to be reduced, but this may be an over simplification. Columnar epithelium in the oesophagus could regenerate from the residual glands, and subsequently be vulnerable to neoplastic transformation. Only long term follow up of large numbers of patients such as those treated in this report can answer this question.

In the short term, there is more potential in looking at ways to improve treatment. The key is to find a technique that will destroy the full thickness of mucosa reliably without damaging the underlying muscle. In this paper, it is clear that there is no selectivity of effect between mucosa and muscle. This is not surprising as the biological effect of the APC is just due to local deposition of heat. The same would be expected with any technique that produces its effect by heating the tissue, such as multipolar electrocoagulation or a KTP laser. Two patients developed an oesophageal stricture severe enough to require dilatation, presumably because the APC had necrosed some muscle, which healed with scarring. The challenge is thus to deliver enough energy uniformly over the Barrett’s oesophagus to destroy the mucosa but not to damage the muscle. As the narrow beam is moved over the area being treated under direct vision, and the result judged just on the immediate visual effect, I think it unlikely that it will be possible to improve much on the results described in this paper, especially as the thickness of the mucosa may vary with the degree of distension of the oesophagus at the moment each shot is fired.

A technique like photodynamic therapy (PDT) that treats all the mucosa uniformly would be more attractive. This involves systemic administration of a photosensitising drug and subsequent circumferential illumination of the affected segment of oesophagus with low power red light, usually from a laser. A variety of light delivery devices are being developed for this, including cylindrical transparent plastic devices and balloons with a central diffusing fibre that can be inflated in the oesophagus. The biological effect is photochemical rather than thermal and relatively sparing of connective tissues like collagen and elastin. However, studies using the photosensitising agent photofrin have shown that, as with the APC, there is no selectivity of necrosis between mucosa and muscle and strictures may occur.

A more promising photosensitising agent for this application is 5-aminolaevulinic acid (ALA). In vivo, this is converted to the photoactive derivative, protoporphyrin IX (PPIX). In contrast to photofrin, which can be found in all layers of the oesophageal wall, PPIX localises mainly in the mucosa and experimental studies have shown that this can be exploited to give selective necrosis of mucosa without damage to underlying muscle. This is exactly what is required to treat circumferential zones of Barrett’s oesophagus. Two important clinical studies have been published using ALA. Neither described any strictures after treatment, which suggests that the muscle layer is not affected, but both reported residual Barrett’s glands under areas of regenerated squamous mucosa, so the problems are not yet all solved. Most clinical studies using ALA in the gastrointestinal tract have reported that the necrosis produced is very superficial using the maximum dose of ALA that can be tolerated by mouth (60 mg/kg, limited by first pass metabolism in the liver).

Thus the next challenge is to find a way of increasing the depth of mucosal necrosis produced using ALA and seeing if this can be achieved without putting the muscle layer at risk. Options currently being explored are to give ALA intravenously, to increase the tissue concentration of PPIX either by using ALA esters or by adding an iron chelating agent (which slows down the final conversion of PPIX to haem), and to fractionate the light dose as experimental studies have shown that a single break of 150 seconds part way through illumination can increase the area of necrosis produced by a factor of four. However, none of these options has yet got beyond animal studies.

The results reported here by Van Laethem et al are the best that can be expected using the APC. If the few Barrett’s glands remaining after treatment do not matter (and it will be years before we can answer this question), and occasional strictures are acceptable (as they seem to respond well to dilatation), the APC could become the treatment of choice as the procedure is relatively simple, safe and cheap. PDT with photofrin is probably inappropriate for Barrett’s because of the risk of strictures and the long period of skin photosensitivity. It is more appropriate for treating small, locally invasive carcinomas.PDT with ALA has the greatest potential for complete destruction of Barrett’s mucosa without causing strictures, but more basic work is required to find out how best to use it.

In the current state of knowledge, it is doubtful whether any form of endoscopic therapy for Barrett’s oesophagus is appropriate other than in the context of clinical trials, unless there is evidence of severe dysplasia and the patient
Progress in idiopathic bile acid malabsorption

Bile acid malabsorption, whether caused by an inborn absence of the ileal transport system or by resection of the terminal ileum, causes diarrhoea because of the secretory effect of malabsorbed dihydroxy bile acids in the colon. There is now increasing evidence that bile acid malabsorption is also present and plays a causal role in many patients with intermittent or chronic diarrhoea who have no ileal pathology. Many of these patients have been labelled with the diagnosis of irritable bowel syndrome. This issue, Fracchia et al (see page 812) provide new information on this syndrome by defining biliary bile acid and lipid composition in 13 well characterised patients with idiopathic bile acid malabsorption.

Bile acids are secreted by the liver entirely in conjugated form. The conjugated bile acid anion is impermeable to cell membranes and too large to pass the paracellular junctions of the biliary and intestinal tract. The highly efficient conservation of bile acids, which is responsible for the accumulation of a recycling bile acid pool, results from both carrier mediated and passive absorption. Carrier mediated absorption is mediated mainly by an apical transporter located in the ileal enterocyte. This transporter, which has been cloned and characterised by Dawson and colleagues, is termed the apical bile salt transporter (abst) because it is also present in the renal tubular epithelial cell and in the cholangiocyte. Passive absorption of unconjugated bile acids that are formed by bacterial enzymes present in the distal small intestine and colon also contributes to the efficient conservation of bile acids. The combination of active and passive absorption of bile acids in the small intestine means that in health, probably less than 5% of bile acids that are secreted into the small intestine enter the colon.

The efficiency of bile acid absorption, the chemical complexity of the spectrum of conjugated and unconjugated bile acids that are absorbed, and the intrinsic variability of first pass hepatic extraction mean that detection of mild degrees of bile acid malabsorption by examining the spillover of bile acids into the systemic circulation is unlikely to be successful. What seems preferable is to measure what is not absorbed using a labelled bile acid that is absorbed solely by the ileal abst and is resistant to bacte-rial deconjugation. Ideally the label should have a short physical or biological half-life and be easily measured.

All of these desirable attributes were achieved in a fruitful collaboration between George Boyd, Professor of Biochemistry at Edinburgh University, now deceased, and his radiochemical colleagues at Amersham who synthesised a derivative of cholic acid in which a 76Se atom was inserted between the β (C23) and γ (C22) carbon atoms of the side chain. The resulting seleno-(homo)-cholic acid was conjugated with taurine to give seleno-homochoyltaurine, abbreviated SeHCAT. SeHCAT is handled by the liver and the intestine quite similarly to taurocholate (also called cholytaurine), but is more resistant to bacterial deconjugation (and dehydroxylation).

How should this bile acid surrogate be used to detect ileal bile acid malabsorption? The most commonly used technique is to measure total body radioactivity before and seven days after administering SeHCAT. This approach is simple, but can be influenced by colonic transit time. Nonetheless, using ileal resection patients as the gold standard, Fellous and colleagues in a recent meticulous study showed that the seven day SeHCAT retention test gave a sensitivity of 79% and a specificity of 90%. Earlier, in an attempt to correct for variability in colonic transit, Ferraris et al administered SeHCAT together with a non-absorbable marker and determined the ratio in faeces. They showed that this approach was preferable because it was unaffected by colonic residence time.

A still more sensitive way of detecting bile acid malabsorption using SeHCAT is to measure the radioactivity located in the gall bladder area each day for several days. By plotting the natural logarithm of radioactivity against time, one can obtain the fractional turnover rate of the SeHCAT pool as the metabolism of most bile acids can be described by first order kinetics. Such an approach is based on the unproved assumption that most bile acids are stored in the gall bladder during the fasting state in the morning and that radioactivity in the gall bladder can be distinguished from that in the small and large intestine.

Fracchia and colleagues report measurements of biliary bile acid and biliary lipid composition in 13 patients with idiopathic bile acid malabsorption, and thus extend considerably our knowledge of this syndrome. The diagnosis of idiopathic bile acid malabsorption was based on the finding of an increased fractional turnover rate of SeHCAT and the lack of small intestinal pathology based on careful radiological and endoscopic studies including enteroclysis to exclude mucosal atrophy in the ileum. Fracchia and colleagues showed that biliary lipid composition, including biliary cholesterol saturation, and biliary bile acid composition did not differ significantly from those of control subjects who were...
Urokinase receptor is a key player in tumour progression

Cell–cell and cell–extracellular matrix (ECM) interactions are essential for cell migration, tissue remodelling, angiogenesis, and tumorigenesis. Pericellular proteolysis of cell surface molecules and ECM provides crucial information in the local environment. Urokinase (uPA) plays an important role through the activation of plasminogen to plasmin, which regulates degradation of elements within the ECM, such as fibrin, fibronectin and lamin, and proteolytic activation of growth factors, including hepatocyte growth factor (HGF), basic fibroblast growth factor (FGF-2) and transforming growth factor β (TGF-β). Plasmin also activates the proenzymes of the matrix metalloproteinases (MMPs), such as MT1-MMP, MMP-2 and MMP-9. uPA activation is regulated by its specific cell surface receptor, urokinase receptor (uPAR). Binding of uPA to its receptor (uPAR) accelerates uPA activation from an inactive proenzyme (pro-uPA). The activity of plasminogen activators can be regulated by the specific inhibitors, plasminogen activator inhibitor 1 (PAI-1) and plasminogen activator inhibitor 2 (PAI-2). The urokinase system is implicated in tumour cell invasion on a basis of genetic and functional differences between uPA activity in metastatic tumours. In particular, uPAR expression on the surface of neoplastic cells is crucial for tumour invasion and metastasis. Overexpression of uPAR has been reported in several types of human carcinoma including gastric cancer, pancreatic cancer and colorectal cancer, and a high uPAR concentration in resected colorectal tumours is an independent and significant prognostic factor for five year overall survival.

During cell migration, the expression of the plasminogen activator system is upregulated. uPAR is distributed over the entire cell surface of non-migrating cells, whereas it is polarised towards the leading edge of migrating cells where it increases plasminogen activity to facilitate cell migration. Although uPAR is attached to the cell membrane only by a glycosyl phosphatidyl inositol (GPI) anchor, which is added after translation, it is also a genuine receptor which induces an intracellular signal. Recent studies have shown that binding of uPA to uPAR activates cellular protein tyrosine kinases, the protein kinase C pathway and mitogen-activated protein (MAP) kinase.

See article on page 798

kinases. Moreover, a direct signalling pathway utilising the Jak/Stat cascade and a second signal transduction mechanism via Src-like protein tyrosine kinases have been implicated in its signalling. Interactions of PAI-1 and uPAR with the extracellular matrix protein vitronectin (VN) and integrin receptors have been reported. Excess PAI-1 may promote cell migration by blocking cellular adhesion to VN and/or promoting detachment of uPAR-bearing cells, and uPAR changes the adhesive properties of integrins. uPAR forms stable complexes with activated integrins to inhibit their usual adhesive function and promote adhesion to VN mediated by the distinct binding site on uPAR. Thus, uPAR is a multifunctional cellular receptor that is involved in activation of proteolytic cascades, altered cell adhesion and intracellular signalling leading to tumour invasion and metastasis.

Various genetic abnormalities, including loss of function of tumour suppressor genes, activation of proto-oncogenes and deficiencies of DNA mismatch repair genes, are thought to contribute to steps in the adenoma–carcinoma sequence in colorectal neoplasia. Cellular transformation often results in a dramatic increase in the activation of the plasminogen activator system, especially urokinase. Kunz et al showed that wild type p53 represses transcription of the uPA and tPA gene through a non-DNA binding mechanism. However, the relation between uPAR expression and tumorigenesis has remained elusive. In this issue Suzuki et al (see page 798) show that uPAR expression increases during the transition from adenoma to invasive carcinoma in colorectal epithelium. uPAR expression was detected in 30% of colorectal adenomas and 85% of invasive carcinomas by in situ hybridisation. Importantly, they show that the frequency of uPAR gene expression was significantly increased in severely dysplastic adenomas compared with mildly or moderately dysplastic adenomas, and in Dukes’ stage B or C cancer compared with Dukes’ A cancer. These data implicate uPAR expression in the progression for normal colonic epithelium to an invasive carcinoma. How is the expression of this multifunctional cellular receptor regulated?

uPAR expression is upregulated by a variety of growth factors, including epidermal growth factor (EGF), FGF-2 and HGF, and by phorbol ester. Raised uPAR expression in colon cancer cells is largely a consequence of constitutive activation of the extracellular signal regulated kinases 1 (ERK-1) dependent pathway. Furthermore, our own data suggest that signalling through the tissue factor (TF)/factor VIIa (FVIIa) pathway results in upregulation of uPAR gene expression and enhanced invasion of pancreatic cancer cells in vitro. These data suggest that the expression of the components of the urokinase system depends upon a complicated series of paracrine interactions. Therefore, it is possible that uPA and/or PAI-1, which are expressed by local stromal cells, are assembled at the surface of the uPAR bearing tumour cells and the activated uPAR system itself then contributes to paracrine regulation of growth factors and MMPs.

Clearly, the components of the urokinase system, especially uPAR, are attractive targets for cancer therapy.

**Does laser lithotripsy hit the target?**

Ever since it was generally concluded that endoscopic retrograde cholangiopancreatography (ERCP) and sphincterotomy was the treatment of choice for choledocholithiasis, big bile duct stones have remained a major challenge for the endoscopist. Extending a sphincterotomy increases risk of bleeding and perforation, mechanical lithotripters are generally expensive, cumbersome to use, fragile, and fail to grasp the stones effectively in a significant proportion of cases. Intraductal sutures such as mono octa-
noin or methyl tert butyl ether are ineffectual or dangerous, or both. The somewhat defeatist approach of placing stents in elderly patients can lead to stent migration with occasional serious consequences or the formation of multiple stones above the stent, with the consequent risk of further cholangitis. There is probably a place at a few referral centres for extracorporeal shock wave lithotripsy (ESWL) but this requires some sort of biliary catheter to deliver x-ray contrast medium to facilitate targeting, which usually means at least two ERCPs in addition to the lithotripsy sessions. Furthermore, not all stones fragment easily and the capital costs and low usage mean that endoscopists must borrow sessions from their urological colleagues in most instances. One must not forget that surgery, despite its risks, may sometimes be the best option, but this is the ultimate admission of defeat by the endoscopist.

One approach which has spawned several publications but has not achieved much “market penetration” is contact lithotripsy. The initial, cheaper, electrohydraulic shock wave machines were rapidly shown to be very effective not only at fragmenting stones but also at punching holes through the bile duct wall unless every shot was clearly on target. Targeting is anything but easy when vision is obscured by clouds of gallstone fragments.

Subsequently a variety of laser techniques have been used. The coumadin pulsed-dye laser was intended, by choice of wavelength, to avoid damage to soft tissues through the elimination of absorption by haemoglobin but this was only partially successful and perforation can still occur, at least in animal models. Many ingenious mechanical devices, such as balloon catheters and wire guided Dormia baskets were developed in an attempt to improve targeting by x-ray monitors but in a three dimensional system such methods were always open to error and the use of miniscopes, delivered either percutaneously or via a “mother and baby” per oral system became more popular. Popular is only a relative term, however, for the difficulty of two skilled endoscopists, preferably close friends, manipulating one scope through the other in the deep recesses of the intrahepatic biliary tree while listening with a long stethoscope to check for good stone contact as one of them depresses the laser foot pedal while simultaneously observing both x-ray and endoscopy monitors and keeping the field of view constantly flushed of fragments, should not be underestimated. For these reasons the percutaneous approach gained ascendancy but both continue to suffer from the targeting problem which makes them very user unfriendly. The alternative approach, to develop a laser system which “knew” when it was aimed at a stone and only fired then was followed chiefly in Austria and Germany where at least three units have used the Rhodamine 6G pulsed dye laser with optical stone detection system produced by Telemit of Munich, including Hochberger et al who have published their latest results in this issue (see page 823). This technical advance means that it is no longer crucial to check that every shot of the laser is aimed correctly, as the power is extinguished after 5–8% of a shot is delivered, unless the returning reflected light indicates a hard target. Thus, radiologically assisted targeting, as in conventional ERCP, is all that is necessary and in their series of 60 patients accumulated over five and a half years, 87% fragmentation and duct clearance was achieved, albeit with five serious complications. In the three published series on this laser so far, 114 patients have been treated, 103 (90%) successfully. The biggest news for endoscopists, however, is that 47 of the 60 patients in the present study were treated by conventional ERCP with x-ray fluoroscopic targeting alone. This blind firing does seem to increase the time required for fragmentation, however, as three times as many pulses are cut off on the grounds of bad targeting despite the use of balloons and wire guided baskets to improve aim. In their earlier study the authors admitted that one third of the patients required additional ESWL to achieve sufficient fragmentation for complete stone clearance. A corresponding figure is not available in the present study. Since sessions could incorporate up to one hour of laser firing and a mean of 1.8 sessions per patient, the procedure remains something of a test of endurance for both patient and staff.

However, according to Hochberger et al this paper is something of a historical document as they are currently using a piezo-acoustic stone detection system coupled to a Q switched NdYAG laser at only one third of the cost of the laser detailed in the present study and with greater effectiveness. Time will tell. In the meantime, why have so few centres purchased Rhodamine 6G lasers? I think at present that most people rely on the methods outlined in the first paragraph and until the “best buy” laser is built it would be better to wait a little longer. However, at least one or two centres in the UK should be investigating this additional method of managing large bile duct stones rather than leaving it all to our continental colleagues.

M. L. WILKINSON

Gastroenterology Unit,
5th Floor,
Thomas Guy House,
Guy’s Hospital, London SE1 9RT, UK

A light at the end of the tunnel

S G BOWN

Gut 1998 43: 737-738
doi: 10.1136/gut.43.6.737

Updated information and services can be found at:
http://gut.bmj.com/content/43/6/737

These include:

References
This article cites 9 articles, 3 of which you can access for free at:
http://gut.bmj.com/content/43/6/737#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/